PULM Forex ziņas

Pulmatrix Announces Positive Top Line Results In Phase 1 Study With PUR3100 For Acute Migraine

Biopharmaceutical company Pulmatrix, Inc. (PULM) announced Wednesday the successful completion of a Phase 1 trial evaluating safety and pharmacokinetics of PUR3100 in healthy volunteers for the treatment of acute migraine.

RTTNews | 763 days ago

Noteikumi | Privātums | Lapas karte | Site Map Calendar

HIGH RISK WARNING: Foreign exchange trading carries a high level of risk that may not be suitable for all investors. Leverage creates additional risk and loss exposure. Before you decide to trade foreign exchange, carefully consider your investment objectives, experience level, and risk tolerance. You could lose some or all of your initial investment. Do not invest money that you cannot afford to lose. Educate yourself on the risks associated with foreign exchange trading, and seek advice from an independent financial or tax advisor if you have any questions. Any data and information is provided 'as is' solely for informational purposes, and is not intended for trading purposes or advice. Past performance is not indicative of future results.

EURUSD	1.03953	GBPUSD	1.25009	AUDUSD	0.62801
USDJPY	152.406	USDCAD	1.43233	USDCHF	0.90185